An observational study in Heart Failure With Reduced Ejection Fraction, sponsored by Rigshospitalet, Denmark. Recruiting at 6 sites in Denmark. Open to participants aged 19 Years to 74 Years. Per ClinicalTrials.gov, last updated 2022-11-01.
Sponsored by Rigshospitalet, Denmark · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Heart Failure by Rigshospitalet, Denmark — 4 open to participants now, 4 under way, none of them phase 3. Heart Failure · Rigshospitalet, Denmark.
Among the 17 studies in Heart Failure by Rigshospitalet, Denmark, this one is the only one that started in 2022, is one of 6 observational ones, and was the 15th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →4 of the 17 studies in Heart Failure by Rigshospitalet, Denmark are open now, in 4 countries. Recruiting first, the newest first:
Rigshospitalet, Denmark · Sites in Denmark, Finland, Norway and 1 more country
Ages 18–99
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 19 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 60 across the 10 interventional studies, 222 across the 6 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Rigshospitalet, Denmark is the lead sponsor of 1,004 studies on the registry; 173 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Heart Failure by Rigshospitalet, Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the Screening for Advanced heart failure IN stable ouTpatientS (SAINTS) study is to determine the prevalence of advanced heart failure (HF) in symptomatic patients with HF and reduced left ventricular ejection fraction (HFrEF), corresponding to the New York Heart Association functional class II-III.
Recognition of advanced HF is a challenge for physicians and under referral for advanced management is a considerable problem. There are excellent treatment options for patients with advanced HF, i.e. heart transplantation or left ventricular assist device (LVAD) implantation, and outcomes with these therapies are considerably better if patients are treated before irreversible end-organ damage occurs. International consensus highlights the importance of timely recognition and referral of these patients to advanced HF centers.
The investigators aim to screen patients with symptomatic HFrEF who are followed in Danish HF clinics in the Copenhagen region with echocardiography, cardiopulmonary exercise test, 6 minute walk test, and NT-proBNP. The investigators hypothesize that 20% of patients with symptomatic heart failure followed in HF clinics in the Copenhagen Region will fulfill the modified criteria for advanced HF from the HFA-ESC (primary end-point in the study)(Reference 1). Patients who are identified with advanced HF will be offered right heart catheterization, guided by ultrasound and inserted through the internal jugular vein, determining pulmonary capillary wedge pressure, cardiac index, central venous pressure, mean pulmonary artery pressure, and central venous oxygen saturation. Patients not fulfilling criteria for advanced HF will be offered right heart catheterization consecutively until 50 patients have been examined (this group will be a comparator group to the patients with advanced HF).
Patients identified with advanced HF will be offered listing for HTx or LVAD if an indication without a contraindication is present. Patients who fulfill the primary endpoint of modified HFA-ESC criteria for advanced HF, and are ineligible for, or unwilling to undergo HTx or LVAD implantation will be invited to participate in the SAINTS B study.
Number of patients and sample size More than 3000 patients are followed in the HF clinics on Zealand including the greater Copenhagen region. The investigators plan to include 400 patients in the primary outcome analysis (SAINTS A) and hypothesize that 20% will fulfill the modified criteria for advanced HF.
Statistical analysis Descriptive statistics will be reported as mean +/- standard deviation (SD) or median (interquartile range (IQR)) depending on distribution. Comparisons between groups at baseline will be performed by unpaired t-tests for normally distributed continuous variables, by the Mann-Whitney U test (Wilcoxon rank-sum) for non-normally distributed continuous variables and χ2 or Fisher's exact test for categorical variables.
The primary outcome will be analyzed as the proportion n (%) of included patients who fulfill the modified HFA-ESC criteria for advanced HF. As for secondary outcomes, the investigators will analyze the proportion n (%) of patients who within the first 3 months are; 1) offered heart transplant listing, 2) offered LVAD implantation, 3) listed for HTx and 4) undergoing LVAD implantation. Further, comparisons of invasive hemodynamics, CPET measures, 6MWT, QoL and NTproBNP levels between patients with and without advanced HF will be made using an unpaired t-test or the Mann-Whitney U test for non-normally distributed continuous variables.
Patients followed in Danish HF clinics in the Copenhagen region.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: Cardiopulmonary exercise test, NT-proBNP, Echocardiography, 6 minute walk test, Right heart catheterization
Screening for advanced HF with modified criteria from the Heart Failure Association of the European Society of Cardiology
Proportion of patients screened who fulfill advanced HF criteria using a modified HFA-ESC definition
Modified HFA-ESC criteria for advanced HF defined as: • LVEF ≤ 30% as estimated by echocardiography AND • Peak oxygen uptake (VO2peak) \< 12 ml/kg/min (14 if on betablocker) with a Respiratory Exchange Ratio (RER) \> 1.05 OR \< 50% expected for age and gender OR 6 minute walk test (6MWT) distance \< 300 meters AND • N-terminal pro B-type natriuretic peptide (NTproBNP) \> 2000 pg / ml
Time frame: At time of screening
Proportion of patients offered heart transplant listing < 3 months after primary outcome
Time frame: 3 months after meeting modified HFA-ESC criteria for advanced HF
Proportion of patients offered LVAD implantation < 3 months after primary outcome
Time frame: 3 months after meeting modified HFA-ESC criteria for advanced HF
Proportion of patients listed for heart transplantation < 3 months after primary outcome
Time frame: 3 months after meeting modified HFA-ESC criteria for advanced HF
Proportion of patients undergoing LVAD implantation < 3 months after primary outcome
Time frame: 3 months after meeting modified HFA-ESC criteria for advanced HF
Pulmonary capillary wedge pressure (PCWP) in mmHg compared between patients with, and without advanced HF
Measured during right heart catheterization
Time frame: Within 30 days from screening
Cardiac index (CI) in l/min/m2 compared between patients with, and without advanced HF
Measured during right heart catheterization
Time frame: Within 30 days from screening
Central venous pressure (CVP) in mmHg compared between patients with, and without advanced HF
Measured during right heart catheterization
Time frame: Within 30 days from screening
Mean pulmonary artery pressure (mPAP) in mmHg compared between patients with, and without advanced HF
Measured during right heart catheterization
Time frame: Within 30 days from screening
Central venous oxygen saturation in % compared between patients with, and without advanced HF
Measured during right heart catheterization
Time frame: Within 30 days from screening
Peak oxygen uptake (VO2peak) in ml/kg/min compared between patients with, and without advanced HF
Measured during cardiopulmonary exercise test
Time frame: At time of screening
Peak respiratory exhange ratio compared between patients with, and without advanced HF
The ratio between metabolic production of CO2 and the uptake of O2 measured during cardiopulmonary exercise test
Time frame: At time of screening
Minute ventilation-to-carbon dioxide output slope (VE/VCO2) compared between patients with, and without advanced HF
The ratio between metabolic production of CO2 and the uptake of O2 measured during cardiopulmonary exercise test
Time frame: At time of screening
Peak Borg scale score compared between patients with, and without advanced HF
The Borg scale score is a rating of perceived exertion on a scale from 6-20, with 6 representing at rest, and 20 the most strenuous exercise imaginable. Measured during cardiopulmonary exercise test
Time frame: At time of screening
6 minute walk test compared between patients with, and without advanced HF
Time frame: At screening
Quality of Life (Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time frame: At screening
NT-proBNP compared between patients with, and without advanced HF
Time frame: At screening
Plan to share: Undecided
Started Oct 2022 (actual). Primary completion is estimated for Dec 2025, 38 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 38 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.